Maintain Underweight at 30-50% position; pre-commit Q3 rules and hold for dividend carry into binary catalyst
Maintain Underweight at the existing 30-50% position, $89.50 stop, $95 protective puts as defensive insurance, pre-committed Q3 rules, two-of-four re-engagement framework post-Q3, $97 price target reflecting base-case breakdown risk if Q3 disappoints. The dividend yield (2.61%) pays for the wait; the wait must be executed with discipline, not drift. DO NOT redeploy trim proceeds into AI/momentum names at highs. Capital preservation is a return.
| Position | Action |
|---|---|
| Current position is 30-50% of target weight | DO NOT trim further, DO NOT add |
| Q3 Beat: EPS +5%+ with maintained/raised guidance | Hold residual; add on close above 200 SMA ($103.14) on volume >20M shares |
| Q3 Miss: EPS -5% or guide-down below $6.00 | Exit residual next session at market |
| Q3 In-line: EPS within ±5% | Hold with trailing stop tightened to $96 |
ABT is a high-quality compounder in a temporary technical washout, sitting at a forward multiple of 16.07x that doesn't reflect its $7.2B annual free cash flow, 50-year dividend track record, and dominant CGM franchise.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 100.15 | bearish |
| close_50_sma | 106.84 | bearish |
| close_200_sma | 103.14 | bearish |
| rsi | 29.73 | bullish |
| macd | -2.37 | bearish |
| macds | -1.82 | bearish |
| macdh | -0.54 | neutral |
| boll | 102.21 | bearish |
| boll_ub | 107.51 | bearish |
| boll_lb | 96.90 | bearish |
| vwma | 101.37 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Two of: (a) close above 200 SMA on volume >20M, (b) MACD histogram higher low from -0.54, (c) RSI bullish divergence at oversold, (d) forward EPS reaffirmation at $6.00+
Then: Begin re-engagement framework
Technical indicators are showing exhaustion rather than continuation — oversold conditions combined with decelerating momentum and a Bollinger Band breach historically mark capitulation moves that reverse.
↩ rebuts: “The bear admits RSI is oversold but argues oversold doesn't mean automatic buy; the spring 2026 analog stayed oversold for weeks.”
EV: +10-20% (mean reversion upside, plus further upside if Q3 print confirms bull case) · concedes: The technical trend is down — the bear is correct on the immediate price action; Near-term earnings will be weighed down by elevated acquisition-related amortization and integration costs in Q2 and Q3; The $20B acquisition does increase leverage and creates integration risk if management fails to execute
The chart is the market's collective view of fundamentals, and ABT's breakdown signals structural problems: a $20B acquisition transformed the balance sheet (net tangible book negative, 518% debt increase), the technical setup shows 5-6 bearish signals with a death cross imminent, and the "16x forward P/E" requires 96% EPS growth that is the bull's best case, not the base case.
· concedes: RSI at 29.73 is technically oversold; Dividend yield of 2.61% provides some income support; Possible tactical bounce to $100-103; Q3 earnings catalyst exists (~10% probability of positive surprise); US recession odds at 8% are historically supportive for defensive names
→ vs conservative: Death cross is a lagging indicator being treated as leading; 16% correction already absorbed distribution—the risk is in the price, not the pattern
→ vs conservative: 1.77 PEG ratio argument reversed—the market is paying for recovery only if it materializes, meaning downside is in and upside isn't, which is exactly the asymmetry risk-takers seek
→ vs conservative: Integration risk overweighted; at 2 quarters in, acquisitions of this size historically take 4-6 quarters to normalize—there's substantial recovery runway left
→ vs conservative: Macro headwinds overweighted; actual data (jobs miss, easing yields, 8% recession odds) supports defensive compounders like ABT with 0.586 beta
→ vs conservative: Pattern risk on death cross overweighted; patterns are descriptive, not predictive in isolation
→ vs neutral: Waiting for Q3 earnings is the most expensive sentence in trading; by the time they confirm, the move will be 10-15% gone and they'll be buying at 110 instead of capitulation low at 97.50
→ vs neutral: Patience is being treated as a position; in a name with this mean reversion setup, every day without positioning cedes entry to algorithmic traders who detect the same oversold signals
→ vs neutral: Entry cost for waiting is quantifiable at 5-8% worse entry—that's a real cost the neutral analyst is ignoring
→ vs conservative: Negative tangible book value is an accounting artifact for a franchise with 7.2 billion in free cash flow, not a going-concern issue
| atr | 2.30 | neutral |
Support: 96.9 · 95.06 · 93.25 · 89 | Resistance: 100.15 · 102.21 · 103.14 · 106.84 · 107.51
ABT is in a confirmed multi-timeframe downtrend with price at 97.50, down 16.4% from the August 2026 high of 116.67, establishing a textbook lower-high/lower-low sequence with no basing signs. Price is below all key moving averages (10 EMA at 100.15, 200 SMA at 103.14, 50 SMA at 106.84) with declining VWMA confirming broad-based institutional selling. RSI at 29.73 and today's intraday breach of the Bollinger lower band (95.06 vs 96.90) suggest oversold exhaustion, though MACD histogram deceleration indicates the rate of decline is slowing. Net signal reads 5-6 bearish, 1 bullish (RSI), 1-2 neutral/mixed, with overhead resistance clustered at 100.15-107.51 and layered support at 96.90, 95.06, and ~93.25.
Market Cap
$168.7B
P/E (TTM)
31.55x
Forward P/E
16.07x
PEG Ratio
1.77
Price/Book
3.30x
EPS (TTM)
$3.09
Forward EPS
$6.07
Beta
0.586
Dividend Yield
2.61%
52-Week Range
$81.97–$135.37
50-Day MA
$106.90
200-Day MA
$104.17
TTM Revenue
$46.58B
TTM Net Income
$5.40B
TTM Profit Margin
11.6%
TTM Operating Margin
14.7%
Gross Margin (TTM)
56.8%
ROE
10.6%
ROA
5.3%
Current Ratio
1.376
Cash & Equivalents
$6.80B
Total Debt
$34.05B
Net Debt
$27.24B
Debt/Equity
0.65x
Interest Coverage
10.2x
Goodwill
$35.22B
Other Intangibles
$17.88B
Net Tangible Assets
-$1.04B
Stockholders' Equity
$52.06B
TTM Free Cash Flow
$7.21B
Quarterly Operating Cash Flow
$1.32B
Quarterly Free Cash Flow
$916M
Quarterly Dividend
$1.10B
Annualized Dividend
$4.4B
Buybacks Q2 2026
$180M
Buybacks Q4 2025
$302M
CapEx
$399M
R&D Spend
$767M
Quarterly Interest Expense
$174M
YoY Revenue Growth
+7.8%
Q2 2026 Revenue
$11,164M
Q2 2026 Gross Margin
56.2%
Q2 2026 Operating Margin
12.0%
Q2 2026 Net Income
$1,077M
Q2 2026 Diluted EPS
$0.53
Q1 2026 Revenue
$11,459M
Q1 2026 Operating Margin
19.6%
Q1 2026 Net Income
$1,776M
Q1 2026 Diluted EPS
$0.61
Q4 2025 Diluted EPS
$1.01
Q3 2025 Diluted EPS
$0.94
Q2 2025 Diluted EPS
$1.01
Q1 2026 Purchase of Business
$19.80B
Q1 2026 Long-Term Debt Issuance
$19.86B
Dividend Streak
50+ years
Working Capital Q1 2026
$7.13B
SG&A Q2 2026
$3.74B
Amortization Q2 2026
$422M
Strengths
Concerns
Abbott Laboratories completed a transformative ~$20B acquisition in Q1 2026, financing it primarily through $19.86B in long-term debt issuance. The deal has materially elevated goodwill to $35.2B and net debt to $27.2B while temporarily compressing Q2 2026 operating margins to 12.0% (from ~18% historically) and depressing diluted EPS to $0.53. Despite near-term headwinds including $422M in quarterly amortization and 45% higher interest expense, the company maintains robust free cash flow of $7.21B TTM, a 50+ year dividend streak yielding 2.61%, and an attractive forward P/E of 16.07x that prices in expected EPS recovery to $6.07 (~96% YoY rebound).
Macro: Dovish pivot underway following September jobs miss and easing 10-year Treasury yields; Fed hold regime firmly priced at 96% probability of zero cuts in 2026 with dovish re-pricing tail skewed to upside surprise; soft-landing dominant scenario with US recession odds at 8% (down 2pp week-over-week); cross-current from Iran-driven oil/inflation shock with 47% probability of gas $4.50+ keeping breakevens elevated and capping Fed dovishness; risk-on equity environment (tech-led Dow/S&P/Nasdaq rally) supports defensive growth names like ABT; FRED macro data unavailable so narrative grounded in news headlines and Polymarket-implied probabilities.